Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|September 18, 2016
Who Benefits Most from Morphokinetic Cellular Analysis?
Author(s)Contagion Editorial Staff
Andrew Chasteen from Accelerate Diagnostics, Inc, discusses who will benefit most from Morphokinetic Cellular Analysis, keeping in mind the challenges posed by antibiotic resistance.
Advertisement
Andrew Chasteen from Accelerate Diagnostics, Inc, discusses who will benefit most from Morphokinetic Cellular Analysis (MCA) keeping in mind the challenges posed by antibiotic resistance.
Interview Transcript (slightly modified for readability)
“The ultimate beneficiary of MCA is the patient. [Patients] benefit primarily by having a very optimized approach to their antibiotic regimen. In many cases we hear, especially lately, about antibiotic resistance and the challenges that that poses, certainly for the patient, but also for the clinician. [Clinicians are] in a situation where they have to use the best information that they have in order to optimize and provide the best care as possible. But the reality is, is that they don’t have what they really need, fast enough.”
Advertisement
Related to this article
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement
Trending on Contagion Live
1
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
2
Measles Update: October 2, 2026
3
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
4
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
5